Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases. Its pipeline includes bitopertin (for erythropoietic porphyrias), DISC-0974 (for anemia of myelofibrosis and inflammatory bowel disease), and DISC-3405 (for polycythemia vera and sickle cell disease). The company has no products approved for commercial sale and has not generated any product revenue.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(63,504) | $(34,085) |
| Net Loss Per Share (Basic & Diluted) | $(1.65) | $(1.02) |
| Operating Expenses | $69,524 | $39,946 |
| Research & Development (R&D) | $45,904 | $27,763 |
| Selling, General & Administrative (SG&A) | $23,620 | $12,183 |
| Cash, Cash Equivalents & Marketable Securities | $730,158 | $791,152 |
| Long-Term Debt (Net) | $29,365 | $29,159 |
| Accumulated Deficit | $(573,690) | $(332,087) |
Note: Cash, cash equivalents, and marketable securities are derived from the Balance Sheet ($88,913 + $641,245) and Liquidity section ($730.2 million).
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $29.4 million (86%) compared to Q1 2025, driven primarily by higher operating expenses.
- R&D Expense Surge: R&D expenses increased by $18.1 million (65%). This was largely due to a $5.0 million milestone payment for the DISC-3405 program (triggered by the first patient administration in a Phase 1b trial for a second indication) and increased personnel costs.
- SG&A Expense Growth: SG&A expenses increased by $11.4 million (94%), primarily due to increased headcount, stock-based compensation, and legal/professional fees related to commercialization planning.
- Cash Flow: Net cash used in operating activities increased to $62.2 million from $41.4 million. Net cash provided by investing activities turned positive ($58.3 million) due to maturities of marketable securities exceeding purchases, whereas Q1 2025 saw significant net cash usage in investing activities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($730.2 million) are sufficient to fund operations and debt service obligations into 2029.
- Bitopertin (EPP/XLP): The FDA issued a Complete Response Letter (CRL) in February 2026 regarding the NDA for accelerated approval. The FDA agreed that bitopertin lowers PPIX but determined there was uncertainty regarding the association between PPIX reduction and clinical benefit (sunlight exposure). The company plans to submit a response to the CRL following topline data from the APOLLO Phase 3 trial, expected in Q4 2026, with an anticipated FDA decision by mid-2027.
- DISC-0974: Initial data from the RALLY-MF Phase 2 trial was reported in December 2025. Updated data is expected in June 2026, with topline data in Q4 2026.
- DISC-3405: Phase 1b trials in Sickle Cell Disease and Phase 2 trials in Polycythemia Vera are ongoing, with initial data expected in Q4 2026.
Risks and Contingencies
- Regulatory Risk: The CRL for bitopertin highlights the risk that surrogate endpoints may not be accepted without clinical outcome data, potentially delaying approval.
- Capital Requirements: The company expects to continue incurring significant losses and may need to raise additional capital in the future.
- Debt Covenants: The company has a $30 million term loan (Hercules Loan Agreement) with a minimum cash covenant effective January 1, 2027, unless market capitalization exceeds $1.0 billion.
- Intellectual Property: Reliance on licensed IP from Roche, AbbVie, and Mabwell; risk of patent expiration or challenges.
Investor Verification Checklist
- Bitopertin Regulatory Path: Verify the specific requirements outlined in the FDA's February 2026 CRL and the timeline for the APOLLO Phase 3 trial topline data (Q4 2026).
- Cash Runway: Confirm the $730.2 million liquidity position and the assumptions regarding the ability to fund operations through 2029 without additional financing.
- Debt Obligations: Review the terms of the Hercules Loan Agreement, specifically the minimum cash covenant triggers starting in 2027 and the "End of Term Charge" of 6.75%.
- R&D Milestones: Monitor upcoming data readouts for DISC-0974 (June 2026) and DISC-3405 (Q4 2026) to assess pipeline progression.
- Stock-Based Compensation: Note the significant increase in stock-based compensation ($11.9 million in Q1 2026 vs. $6.4 million in Q1 2025) and its impact on future burn rates.